Sarissa Capital Management L.P. is an investment fund managing more than $782 billion ran by Alexander Ph.d.. There are currently 11 companies in Mr. Ph.d.’s portfolio. The largest investments include Alkermes plc and Biogen Inc, together worth $431 billion.
As of 8th May 2023, Sarissa Capital Management L.P.’s top holding is 8,964,640 shares of Alkermes plc currently worth over $253 billion and making up 32.3% of the portfolio value.
Relative to the number of outstanding shares of Alkermes plc, Sarissa Capital Management L.P. owns less than approximately 0.1% of the company.
In addition, the fund holds 643,000 shares of Biogen Inc worth $179 billion, whose value grew 3.3% in the past six months.
The third-largest holding is Ironwood Pharmaceuticals Inc worth $172 billion and the next is Innoviva Inc worth $74.4 billion, with 6,614,000 shares owned.
Currently, Sarissa Capital Management L.P.'s portfolio is worth at least $782 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The Sarissa Capital Management L.P. office and employees reside in Greenwich, Connecticut. According to the last 13-F report filed with the SEC, Alexander Ph.d. serves as the Chief Investment Officer at Sarissa Capital Management L.P..
Alexander Ph.d. disclosed a decreased stake in Alkermes plc by 0.4%.
This leaves the value of the investment at $253 billion and 8,964,640 shares.
The two most similar investment funds to Sarissa Capital Management L.P. are Wealthcare Capital Management and United Bank. They manage $782 billion and $783 billion respectively.
Sarissa Capital Management L.P.’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 98.6% of
the total portfolio value.
The fund focuses on investments in the United States as
63.6% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are large-cap stocks.
Stocks with a size of more than $10 billion in market cap make up
18% of the total holdings value.
On the other hand, small-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $20.5 billion.
These positions were updated on May 15th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Alkermes plc |
36.15%
8,964,640
|
$252,713,202,000 | 32.32% |
| Biogen Inc |
No change
643,000
|
$178,773,290,000 | 22.86% |
| Ironwood Pharmaceuticals Inc |
No change
16,390,000
|
$172,422,800,000 | 22.05% |
| Innoviva Inc |
No change
6,614,000
|
$74,407,500,000 | 9.52% |
| Gilead Sciences, Inc. |
36.66%
850,000
|
$70,524,500,000 | 9.02% |
| Mersana Therapeutics Inc |
11.61%
3,800,000
|
$15,618,000,000 | 2.00% |
| Amarin Corp Plc |
79.54%
4,910,000
|
$7,365,000,000 | 0.94% |
| Biocryst Pharmaceuticals Inc. |
44.28%
775,000
|
$6,463,500,000 | 0.83% |
| Vor Biopharma Inc |
No change
618,000
|
$3,324,840,000 | 0.43% |
| Regulus Therapeutics Inc |
No change
185,183
|
$156,943,000 | 0.02% |
| Pear Therapeutics Inc |
No change
500,356
|
$127,591,000 | 0.02% |
| No transactions found | |||
| Showing first 500 out of 11 holdings | |||